30.04.2010 • NewsAkzoNobelQ1 2010

Akzo Nobel Shows Growth in Q1 2010

Akzo Nobel has reported improved volumes in most businesses for the first quarter of 2010, underpinning revenue growth of 6%. Continued margin management and cost reduction programs also contributed to Ebitda growth of 38%. The one-year rolling Ebitda margin reached 13.6%. The company also improved its net income to €81 million and classified National Starch as a discontinued operation.

Commenting on the results, CEO Hans Wijers said,: "We've had a good start to 2010, particularly in higher growth markets, where our performance was strong. While revenue growth across all Akzo Nobel's businesses has been solid, our Q1 performance compares with a particularly weak first quarter in 2009."

Akzo Nobel said it remains on track to achieve its medium-term target of an Ebitda margin of 14% by the end of 2011. The focus on customers, cost reduction and cash generation continues, while investments to capture growth remain a priority, particularly in higher growth markets. Although volumes remain below pre-recessionary levels in most businesses, the company said increases in volume, first evident in Q2 2009, have continued more broadly and are a reason for cautious optimism.

"We expect pressure from further raw material cost increases during the year and remain cautious about the strength of the recovery," Wijers said. "Akzo Nobel ... will also prioritize investments and initiatives to ensure that the company is able to capture growth."

Company

Logo:

AkzoNobel

Christian Neefestraat 2
1077 WW Amsterdam
Netherlands

Company contact







Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.